Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04741009
Other study ID # CAM5776
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date December 16, 2021
Est. completion date August 1, 2025

Study information

Verified date April 2024
Source Cochlear
Contact Paul Reinhart
Phone 612-456-1621
Email preinhart@cochlear.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of the feasibility study is to investigate hearing performance (audiometry and speech perception) using the CI632 in a group of adults (n=15) with low-frequency residual hearing who meet inclusion criteria.


Recruitment information / eligibility

Status Recruiting
Enrollment 15
Est. completion date August 1, 2025
Est. primary completion date August 1, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 69 Years
Eligibility Inclusion Criteria: 1. 18 years-of-age or older at the time of surgery. 2. Low-frequency threshold at 500 Hz = 50 dB HL and high-frequency pure-tone average (PTA), 2000-8000 Hz = 65 dB HL in the ear to be implanted. 3. Pure-tone average (PTA) (0.5k, 1k, 2k Hz) > 30 dB HL in the contralateral ear. 4. CNC word recognition scores (mean of two lists) = 60% in the ear to be implanted and = 80% in the contralateral ear. 5. English spoken as a primary language. 6. Willing and able to provide written informed consent. Exclusion Criteria: 1. Individuals greater than or equal to 70 years at the time of surgery. 2. Duration of severe to profound sensorineural hearing loss > 20 years per self-report. 3. Onset of sensorineural hearing loss, for the purpose of this study, prior to 5 years-of-age. 4. Ossification or any other cochlear anomaly that might prevent complete insertion of the electrode array. 5. Conductive overlay of 15 dB or greater at two or more frequencies, in the range of 250 through 1000 Hz in the ear to be implanted. 6. Hearing loss of neural or central origin. 7. Diagnosis of Auditory Neuropathy. 8. Active middle-ear infection. 9. Medical or psychological conditions that contraindicate undergoing surgery as determined by the Investigator. 10. Unrealistic expectations on the part of the subject, regarding the possible benefits, risks, and limitations that are inherent to the device and/or procedure, as determined by the Investigator. 11. Additional handicaps that would prevent or restrict participation in the audiological evaluations as determined by the Investigator. 12. Unable or unwilling to comply with the requirements of the clinical investigation as determined by the Investigator. 13. Investigator site personnel directly affiliated with this study and/or their immediate family (spouse, parent, child, or sibling). 14. Cochlear employees or employees of a Contract Research Organization (CRO) or contractors engaged by Cochlear for the purposes of this investigation. 15. Currently participating, or has participated in the last 30 days, in another interventional clinical investigation/trial involving an investigational drug or device.

Study Design


Intervention

Device:
CI632 Slim Modiolar Electrode
Cochlear Ltd CI632 cochlear implant with Slim Modiolar Electrode

Locations

Country Name City State
United States Cleveland Clinic Cleveland Ohio
United States University Hospitals Cleveland Ohio
United States Midwest Ear Institute Kansas City Missouri
United States New York University New York New York
United States Georgetown University Washington District of Columbia
United States UMass Memorial Medical Center Worcester Massachusetts

Sponsors (1)

Lead Sponsor Collaborator
Cochlear

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary To characterize hearing performance of the CI632 in an adult population under expanded indications for use. To characterize hearing performance of the CI632 using CNC word recognition in quiet scores with percentage correct words. 14 months
See also
  Status Clinical Trial Phase
Completed NCT00023036 - Clinical and Genetic Analysis of Enlarged Vestibular Aqueducts
Completed NCT03746613 - Clinal Evaluation of Navigation Based Functional Ear Surgery Using Image Guided and Robotically Assisted Techniques N/A
Recruiting NCT05568329 - Appreciation for Music Processed by Hearing Aids N/A
Withdrawn NCT05061758 - A Trial of LY3056480 in Patients With SNLH Phase 2
Completed NCT01434446 - The Effect of Sound Stimulation on Hearing Ability N/A
Completed NCT03212924 - Listening Effort in Cochlear Implant Users N/A
Recruiting NCT06053190 - Effects of Clear Speech on Listening Effort and Memory in Sentence Processing N/A
Completed NCT03718975 - Quality Control of CE-Certified Phonak Hearing Aids - 2018_28 N/A
Completed NCT06025097 - Intra-Tympanic Steroid With PRP Combination in Sensorineural Hearing Loss and Tinnitus. Early Phase 1
Recruiting NCT04102215 - The Efficacy of a Minimally Invasive Direct Cochlear Access Via the HEARO Procedure N/A
Recruiting NCT04108598 - The SeaSHeL National Prospective Cohort Study
Active, not recruiting NCT04750642 - Cochlear Implant With Dexamethasone Eluting Electrode Array N/A
Completed NCT04120116 - FX-322 in Adults With Stable Sensorineural Hearing Loss Phase 2
Recruiting NCT06223724 - Status Telemetry for Cochlear Implantations
Completed NCT02005822 - Congenital Cytomegalovirus: Efficacy of Antiviral Treatment Phase 3
Suspended NCT02616172 - Autologous Bone Marrow Harvest and Transplant for Sensorineural Hearing Loss Phase 1/Phase 2
Completed NCT02259595 - Study to Determine the Safety, Tolerability, and Pharmacokinetic Profile of HPN-07 and HPN-07 Plus NAC Phase 1
Unknown status NCT01902914 - Effectiveness of P02 Digital Hearing Aids Phase 1/Phase 2
Completed NCT00589511 - Nucleus Freedom Cochlear Implant System Pediatric Post-approval Study N/A
Completed NCT03288753 - Comparison Between Neuro 1 and Neuro 2 Cochlear Implant Speech Processors N/A